STRS Ohio’s Quince Therapeutics QNCX Stock Holding History

STRS Ohio’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-41	Closed	-$50K	–	2236
2022 Q1	$50K	Hold	41	–	–	﹤0.01%	1942
2021 Q4	$102K	Buy	41 +20	+95%	+$122K	﹤0.01%	1895
2021 Q3	$375K	Buy	+21	New	+$334K	﹤0.01%	1601
2021 Q1	–	Sell	-38	Closed	-$211K	–	2262
2020 Q4	$211K	Hold	38	–	–	﹤0.01%	1729
2020 Q3	$380K	Hold	38	–	–	﹤0.01%	1472
2020 Q2	$351K	Buy	38 +34	+850%	+$312K	﹤0.01%	1479
2020 Q1	$36K	Hold	4	–	–	﹤0.01%	1828
2019 Q4	$44K	Hold	4	–	–	﹤0.01%	1912
2019 Q3	$19K	Hold	4	–	–	﹤0.01%	1981
2019 Q2	$34K	Buy	+4	New	+$23.9K	﹤0.01%	1978

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

STRS Ohio's QNCX Position: Q2 2022 in Review

STRS Ohio sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 41 shares — an estimated $50K sold.

STRS Ohio first reported a position in QNCX in Q2 2019 and held it in 10 quarters. The position peaked at $380K in Q3 2020. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

STRS Ohio reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
STRS Ohio sold 41 Quince Therapeutics shares in Q2 2022, an estimated $50K.
STRS Ohio first reported a position in Quince Therapeutics in Q2 2019 and held it in 10 quarters.
STRS Ohio's Quince Therapeutics position peaked at $380K in Q3 2020.
66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on STRS Ohio's 13F filing for Q2 2022, filed 25 Jul 2022.